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ABSTRACT 
 
Aims: To determine individual and combined effects of AF (atrial fibrillation) and HF (heart 
failure) on AIS (acute ischaemic stroke) outcomes: in-hospital mortality, length-of-stay and 
post-stroke disability; long-term mortality and stroke recurrence.  
Methods: Prospective cohort study of AIS patients admitted to a UK centre with catchment 
population of ~900,000 between 2004-2016.  Exposure groups were patients with neither AF 
nor HF (reference group), those with AF but without HF, those with HF but without AF, and 
those with AF+HF. Logistic and Cox regressions were used to model in-hospital and long-
term outcomes, respectively. 
Results: 10,816 patients with a mean age±SD = 77.9±12.1 years, 48% male were included. 
Only 30 (4.9%) of the patients with HF but not AF were anticoagulated at discharge. Both  
AF (OR 1.24 95%CI 1.07-1.43), HF (OR 1.40 (1.10-1.79)) and their combination (OR 2.23 
(1.83-2.72)) were associated with increased odds of in-hospital mortality. All three exposure 
groups were associated with increased length-of-stay, whilst only AF predicted increased 
disability (1.36 (1.12-1.64)). Patients were followed for a median of 4.8 and 3.7 years for 
mortality and recurrence, respectively. Long-term mortality was associated with AF (HR 1.45 
95%CI 1.33-1.59), HF (2.07 (1.83-2.36)) and their combination (2.20 (1.96-2.46)). Recurrent 
stroke was associated with AF 1.50 (1.26-1.78), HF (1.33 (1.01-1.75)) and AF with 
HF(1.62(1.28-2.07)). 
Conclusion: The AF-associated excess risk of stroke recurrence was independent of co-
morbid HF.  HF without AF was  alsoassociated with a significant risk of recurrence. Anti-
coagulation for secondary stroke prevention in patients with HF without AF may require 
further evaluation in a clinical trial setting. 
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INTRODUCTION 
The relationship between heart failure (HF), atrial fibrillation (AF) and the outcomes of 
acute ischaemic stroke (AIS) has been previously examined. It has been previously shown 
that both AF and HF are not only associated with an increased risk of AIS1-4, but also with 
increased post-AIS mortality and disability5-13. Furthermore, both AF and HF have been 
linked to increased risk of stroke recurrence14-16.  
Due to the natural course of the two disease entities, they frequently co-exist17-19. This 
proves particularly problematic, since the previously reported impact of HF on AIS outcomes 
may be influenced by AF and vice-versa. Thus, despite previous reports having analysed the 
individual contribution of either AF or HF on stroke outcomes, as well as the impact of AF 
on outcomes of stroke patients with HF8, the combined contribution of the two remains 
largely unknown. 
Given the current lack of understanding of the relative individual versus combined impact 
of these conditions on stroke outcomes, we aimed to quantify these associations using a 
cohort of unselected hospitalised AIS patients. Both in-hospital (death, length-of-stay (LoS), 
disability) and long-term (mortality and stroke recurrence) outcomes were assessed. 
 
METHODS  
 Study participants and design  
Participants were drawn from the Norfolk and Norwich Stroke and TIA Register  
(NNSTR) database using previously defined selection criteria20,21. The NNSTR is a 
prospective UK single-centre hospital-based register. The NNSTR records all stroke 
admission to the Norfolk and Norwich University Hospital (NNUH), the only tertiary centre 
in Norfolk County, England (catchment population 900,000 in 2017). Given the 
demographics of the region, this registry is representative of most Western European 
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populations. Data collection methods have been reported previously20,21. The register 
received ethical approval from the Newcastle and Tyneside National Health Service (NHS) 
and Research Ethics Committee (17/NE/0277) as a research database, which does not require 
individual patient consent. The protocol was approved by the Steering Committee of the 
Register. The study was conducted in accordance with the principles of the Declaration of 
Helsinki (1964) and later amendments.  
Exclusion criteria, outcomes of interests (in-hospital mortality, LoS, disability, post-
discharge long-term mortality and ischaemic stroke recurrence), and selection of study 
covariates were all agreed a-priori. 
Patients admitted with confirmed AIS between January 2004 and December 2016 
were included. In all participants, AIS was diagnosed based on patient history, neurological 
examination, and neuroimaging results. Follow-up data were collected in June 2017, yielding 
a median follow-up of 5.5 and 3.7 years for the mortality and recurrence outcomes 
respectively. Maximum follow-up was 5262 days (14.4 years). Record linkage with the UK 
NHS system ensures a robust ascertainment of co-morbidities and almost complete follow up 
data. Exclusion criteria were applied successively for each stage of the analysis, according to 
analysis-specific requirements (Figure 1). A total of 10,839 AIS patients were initially 
extracted from the database. Patients with missing discharge dates (n = 23) were excluded, 
leading to a starting cohort of 10,816. 
 
Data collection and exposure group definition 
 Data on the exposure variables (HF and AF) were identified from ICD-10 codes based 
on clinical findings and retrieved from the hospital administration database (heart failure 
(I50) and atrial fibrillation and flutter (I48)). Given that our database performed electronic 
record linkage with primary care co-morbidity data, any diagnoses of AF or HF before, 
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during or after the stroke admission were extracted. Given that general practitioners in 
England receive financial incentives to optimise the diagnosis and treatment of certain 
conditions (including AF and HF)22, co-morbidity ascertainment in our databse is robust. Any 
new diagnoses of HF or AF after discharge were extracted as dichotomous variables from the 
NNSTR along with the time when they were first diagnosed and updated in the models.  For 
all the analyses, patients were split into 4 mutually exclusive categories: patients with neither 
AF nor HF, patients with AF but not HF, patients with HF but not AF and patients with both 
AF and HF.  
 
Data collection and confounder selection  
Potential confounders were selected based on existing literature5,6,8-10 and clinical judgement. 
Data on age, sex, Oxfordshire Community Stroke Project classification (OCSP) and relevant 
biochemical and haematological measurements collected on admission (random plasma 
glucose, haemoglobin, total white cell count, albumin, creatinine, urea, CRP (C-reactive 
protein), and INR (International Normalised Ratio)) were collected by electronic record 
linkage. Information on confounding comorbidities were identified from ICD-10 codes based 
on clinical findings and retrieved from the hospital administration database (Supplementary 
Table I). Any diagnoses of a co-morbidity of interest occurring before, during or after the 
stroke admission were extracted. . Co-morbidities were extracted as dichotomous variables 
from the NNSTR along with the time when they were first diagnosed.  
 
Data collection and outcome selection 
 Data regarding our outcomes of interest were extracted from the hospital database. To 
evaluate the stroke-related disability status, we calculated the difference between the 
modified Rankin Score (mRS) after and before the incident stroke and then split these values 
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into tertiles. Data regarding the mortality and recurrence rates were collected using the 
recorded date of death or AIS readmission from the database, respectively. 
 
Statistical Analysis  
 Data were analysed using Stata 15.1 SE (StataCorp. 2017. Stata Statistical Software: 
Release 15. College Station, TX: StataCorp LLC). The Pearson’s chi-squared test was used to 
compare differences in categorical variables across the 4 exposure groups. The Kruskal-
Wallis test and one-way ANOVA were used to compare differences in non-normally and 
normally distributed variables, respectively. The median follow-up time was calculated using 
the reverse Kaplan-Meier method23. The log-rank test was utilised to compare the rates of 
incident dementia over the follow-up period between patients with and without AF. 
 
Handling of missing data  
Thirteen variables (pre- and post-stroke mRS, OCSP, admission random plasma 
glucose, creatinine, sodium, albumin, cholesterol, INR, CRP, haemoglobin, white cell count 
and platelet count) contained missing data (Supplementary Table II). Having explored the 
differences between patients with missing data for each of the variables in question 
(Supplementary Tables III-XV), we have observed that patients with missing data were more 
likely to die in hospital, have a longer hospital stay and have more co-morbidities. We thus 
deemed the data likely to be missing-at-random24. Multiple imputation by chained equations 
algorithm with 20 iterations was implemented to impute the missing data. Biochemical and 
haematological variables were imputed using predictive mean matching25. OCSP and the 
mRS scores were imputed using multinomial logistic regressions. The difference between the 
pre- and post-stroke mRS (∆mRS) was calculated using the imputed variables for each of the 
20 iterations and then divided into tertiles, which were then utilised as the disability outcome. 
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As our database only recorded the National Institutes of Health Stroke Scale (NIHSS) 
routinely for admissions occurring after January 2015, a high frequency (86%) of missing 
data was observed for this variable. We performed sensitivity analyses as a separate model 
including the imputed NIHSS, which did not show any significant change in any of the 
results. 
 
In-hospital mortality 
A multivariable binomial logistic regression was performed to assess the association 
between the exposure groups and in-hospital deaths. The following confounders were 
included, based on clinical judgement and existing literature5,6,8-10: age, sex, OCSP, co-
morbidities (Supplementary Table I), admission plasma biochemical and haematological 
parameters and admission antithrombotic medication. 
 
Length of in-hospital stay and excess disability 
A total of 2035 patients who died in hospital were excluded for this part of the 
analysis, resulting in a cohort of 8781 patients. A binomial logistic regression model was 
used to determine the association between exposure groups and in-hospital LoS greater than 
the cohort median. For the analysis of the excess disability, a multinomial logistic regression 
model with ∆mRS tertiles as the outcomes was utilised. In addion to the same confounders 
used in the in-hospital mortality analysis, the pre-stroke mRS score was also added because 
patients with a high pre-stroke mRS are more likely to fall in the category of patients with the 
lowest excess post-stroke disability.  
 
Post-discharge mortality and AIS recurrence 
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A further 74 patients with missing follow-up information were excluded for the long-
term mortality analysis, yielding a cohort of 8707 patients. All patients with a history of 
previous ischaemic stroke (n = 441) and those who suffered a recurrent stroke in hospital (n = 
273) were further excluded from the AIS recurrence analysis, yielding a cohort of 7933 
patients.   
For both outcomes, a Cox regression model was employed to estimate the long-term 
mortality or recurrence risk associated with each of the exposure groups. Given the 
competing risk of death for the outcome of recurrent ischaemic stroke, cause-specific hazard 
ratios were yielded for this outcome.  
The satisfaction of the proportional hazards assumption was confirmed for both 
analyses. The models were adjusted for age, sex, OCSP, co-morbidities (Supplementary 
Table I) and discharge antithrombotic agents. We additionally controlled for new co-
morbidity diagnoses (including incident haemorrhagic stroke) after hospital discharge as 
time-updated binary variables in the regression model. The long-term mortality analysis was 
also adjusted for incident recurrent strokes. 
 
RESULTS  
Descriptive Statistics 
Table 1 and Supplementary Table XVI display the patient characteristics at 
admission. The statistics for the variables with missing values are displayed for the complete 
cases only. The mean age (SD) was 77.9 (12.1) years and 49% were male. Patients were 
followed up for a median (95%CI) of 2001 (1957-2044) and 1348 (1303-1411) days for 
mortality and recurrence, respectively. There were 6668 out of 10,816 (61.7%) patients with 
neither co-morbidity, 2605 (24.1%) patients with AF only, 611 (5.7%) with HF only and 932 
(8.6%) with both AF and HF. Patients with both AF and HF were the oldest group (mean±SD 
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= 83.5±8.8), followed by patients with only AF (82.2±8.8), patients with only HF 
(80.2±10.7) and patients with neither co-morbidity (75.3±12.8). Patients with AF were more 
likely to be female, regardless of whether they had HF. The highest in-hospital mortality was 
recorded for patients with both AF and HF, followed by patients with HF only and those with 
AF only and patients with neither disease. Among stroke admissions with neither co-
morbidity, AF only, HF only, and those with both AF and HF there were 153 (2.3%), 662 
(25.4%), 30 (4.9%) and 185 (19.9%) patients receiving anticoagulant medications at 
discharge. The patients with both HF and AF had the highest comorbidity burden, followed 
by those with HF only, those with AF only and those with neither HF nor AF. There were 
314 (2.9%) patients with pre-existing dementia. The rates of dementia were significantly 
higher amongst patients with AF than in those without. Patients with AF had a significantly 
higher incidence of dementia in the long-term follow-up than those without (P < 0.001). 
 
In-hospital mortality analysis 
Table 2 and Figure 2 detail the results of the in-hospital mortality analysis. Compared 
to the reference group, patients with both AF and HF had the highest increase in odds (OR 
(95% CI) = 2.23(1.83-2.72)), followed by patients with HF only (1.40(1.10-1.79)) and those 
with AF only (1.24(1.07-1.43)). Sensitivity analyses adjusting for the imputed NIHSS score 
did not show any differences for this outcome. 
 
In-hospital length of stay and disability analysis 
Table 2  details the results of the in-hospital LoS and stroke-associated excess 
disability analyses. The median LoS was 8 days. Compared to the reference group, patients 
with only HF had a 85% increase in the odds of having a LoS greater than median 
(OR(95%CI) = 1.85(1.50-2.28)). Those with both HF and AF experienced an increase in their 
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odds of 66% (1.66(1.38-2.00)), whilst those with AF only had a 29% higher odds for this 
outcome (1.29(1.16-1.44)).  
With membership to the 1st ∆mRS tertile as baseline, none of AF, HF or their 
combination predicted membership of the 2nd tertile. Only patients with AF but not HF were 
more likely to be part of the 3rd tertile (1.36(1.12-1.64)). 
 
Long-term mortality analysis 
Table 3 displays the numbers and rates of post-discharge deaths recorded during the 
follow-up period. There were 1649 (29.1%), 860 (42.9%), 229 (50.7%) and 330 (56.2%) 
deaths recorded in patients with neither co-morbidity, those with AF only, those with HF 
only and those with both AF and HF, respectively. Table 3 and Figure 2 detail the results of 
the long-term mortality analysis. Those with HF only and those with both HF and AF had 
twice the long-term mortality risk of the reference group (HR(95%CI) = 2.07(1.83-2.36) and 
2.20(1.96-2.46)), respectively. Patients with AF  only had a 45% increased risk of long-term 
mortality (HR(95% CI) = 1.45(1.33-1.59)). 
 
Long-term stroke recurrence analysis 
Table 3 displays the number and rate of recurrent ischaemic strokes recorded during 
the follow up. There were  550(10.5%), 233(12.7%), 52(13.0%) and 59(11.5%) recurrent 
events recorded in patients with neither co-morbidity, those with AF only, those with HF 
only, and those with both AF and HF respectively. Table 3 and Figure 2 detail the results of 
the long-term AIS  recurrence analysis. Compared to the reference group,  a higher risk of 
recurrence was associated with patients with AF alone, those with HF alone and those with 
both AF and HF: HR(95%CI) – 1.50(1.26-1.78), 1.33(1.01-1.75 and 1.62(1.28-2.07), 
respectively. 
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DISCUSSION 
 In this large, real-world stroke registry we have found a 24% and 40% increase in 
odds of in-hospital mortality associated with isolated AF and isolated HF, respectively. 
Patients with both AF and HF were over twice as likely to die in hospital compared to the 
reference group. This suggests that the individual effects of each co-morbidity are 
synergistic. Nevertheless, this effect was not identified for the post-discharge outcomes. Our 
long-term mortality results suggest that HF is associated with double the mortality rate 
regardless of whether AF co-existed. Furthermore, isolated AF was associated with a 50% 
excess long-term mortality. In contrast, patients with AF and HF had a 60% increase in the 
stroke recurrence risk, but in patients with isolated HF this only increased by 33%. 
Our data show that patients with HF without AF are at a 30% higher risk of 
recurrence than patients without HF, after adjusting for discharge anti-thrombotics. A 
previous meta-analysis found that co-morbid HF is associated with a twofold increase in AIS 
recurrence16. Nevertheless, this relationship may be also driven by co-existent AF, since up to 
50% of HF patients also have AF17-19 . A previous study showed that the rate of 
cardiovascular events of stroke patients with HF does not differ significantly based on their 
AF status8. Whilst this outcome did include AIS recurrence, it was considered as part of a 
composite outcome. Consequently, we are the first to report on the rates of AIS recurrence in 
patients with HF without AF.  
Previous clinical trials assessing anticoagulation for the prevention of AIS in patients 
with HF without AF have concluded that it was either not associated with better outcomes26, 
or that its risks outweigh the benefits27,28. The latter finding may be consistent with our 
finding that stroke HF patients without AF had at a significant, yet lesser increase in the risk 
of recurrence. Clinical trial post-hoc analyses have determined that increasing severity of 
HF29, lower left ventricular ejection fraction30 and higher levels of N-terminal pro B-type 
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natriuretic peptide29 were risk factors for incident stroke in HF patients without AF. Thus, it 
may be that within our group of patients with HF and no AF there may be certain subgroups 
at a higher risk of recurrent events, whilst others may be at no significantly increased risk. 
We were nevertheless not able to identify any such subgroups due to the lack of those 
parameters in our data. Nevertheless, previous trials assessed the use of anticoagulants for 
primary stroke prevention in HF patients, whilst our study analysed stroke recurrence. Our 
study identifies the need for further trials assessing secondary stroke prevention in patients 
with HF.   
Our results show that in terms of long-term mortality there was no difference between 
HF patients with and without AF. This result is consistent with previous literature8. Our study 
also confirms that AF significantly increases the long-term mortality of AIS patients5,7,8,12,13. 
Unfortunately, we were not able to stratify by the TOAST classification. Given the fact that 
AIS events in HF and AF patients are more likely to be cardioembolic in origin31, the 
observed mortality may also be driven by the fact that AIS cases of the cardioembolic 
subtype have an overall worse prognosis31. Nevertheless, we adjusted for the OCSP 
classification, which may be regarded as a proxy of the TOAST and have controlled for 
discharge anti-thrombotic medications. This finding may also be explained by the association 
between AF and other co-morbidities, such as dementia, that may influence survival. This 
relationship has been described previously32,33 and can also be observed in our sample: 
patients with AF were not only more likely to have pre-existing dementia but also develop 
incident dementia after discharge.  
Our study has several strengths. By stratifying AIS patients in four mutually exclusive 
groups, our study was able to provide novel insights into the real influence of AF and HF on 
the outcomes of AIS patients. We are the first study to report the association between these 
exposure groups and stroke outcomes. The cohort is a large, prospectively identified 
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population of consecutively hospitalised stroke patients. As a record linkage study embedded 
within the UK National Health Service (NHS), the ascertainment of co-morbidities 
throughout the study follow-up as well as discharge medication is robust and we have almost 
100% follow up. Only 0.90% of our initial cohort were excluded due to missing follow-up 
information.We have also been able to adjust for anti-thrombotic medications at discharge, 
thereby minimsing the bias inherent to the non-randomised nature of observational studies. 
There are some limitations worth highlighting. Our database did not record HF 
clinical characteristics. Thus, we have been unable to identify HF patient subgroups that may 
be at a higher risk of recurrent AIS independent of the effects of AF. There was a large 
proportion of missing data for NIHSS, given that routine collection of this variable only 
occurred after 2015. Nevertheless, our sensitivity analyses including the imputed NIHSS 
yield similar results. Furthermore, we controlled for surrogate markers of stroke severity, 
such as the OCSP classification and the post-stroke mRS score. The study population is 
ethnically homogenous. However, both AF and HF are unlikely to have different impact in 
other ethnic groups, as underlined by a Greek study showing similar results8. Furthermore, 
differences may exist in HF case ascertainment and management along the patient 
recruitment timeline. Given the long follow-up time of our cohort, post-discharge changes in 
medication regimens may have been missed, including antithrombotics. This is likely to 
affect patients with more severe strokes, since those are most likely to be initiated on oral 
anticoagulation with a longer delay from the index event34. Our results may thus 
underestimate the recurrence risk in these patients. We may have only been able to account 
for chronic AF in our analyses, since asymptomatic paroxysmal episodes of AF may be 
missed without 24h cardiac rhythm monitoring. Nevertheless, this remains an inherent 
limitation of any large-scale long term follow-up observational study in the absence of 
implantable monitors. According to the REVEAL AF study, up to 40% of patients at a high 
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risk for developing AF experienced at least one episode of AF (>6 minutes) over 30 months 
follow-up35.Nevertheless, our study represents the real-world setting, where patients are not 
routinely under continuous cardiac monitoring. Thus, short episodes of paroxysmal AF may 
remain unrecognised and the required anticoagulant therapy may not be prescribed. Recurrent 
events were ascertained using only the register data, but this is likely to have a high accuracy, 
since it is based on the NHS record system.  
Our study may have several important implications for clinical practice. This study 
shows that HF patients with co-existent AF are at an almost double risk of post-stroke in-
hospital death when compared to their counterparts without AF. Whilst it has been shown 
before on non-stroke cohorts that patients with HF have a worse prognosis when AF co-
exists19, our study indicates that this effect is synergistic in patients with AIS. This warrants 
that special consideration needs to be paid to those patients in the context of stroke care. 
Whether these high-risk patients may benefit from the adoption mechanical endovascular 
recanalization strategies, given that intravenous thrombolysis is more likely to fail in this 
patient subgroup36, remains to be established by further studies. 
 
CONCLUSION 
Our study shows that patients with both AF and HF are at increased risk of mortality 
during their acute stroke admission, with double the risk of those with AF or HF in isolation. 
Subsequently, it may be the case that this subgroup of patients may benefit from personalised 
therapeutic options. Furthermore, our study shows that the excess risk of recurrent AIS 
associated with AF is independent of co-morbid HF and that HF in isolation is also 
associated with recurrent events . Thus, anti-coagulation strategies in stroke patients with HF 
but without AF may require further evaluation in a clinical trial setting. In the meantime, our 
study provides real-world prognostic information for AIS patients with these conditions. 
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 FIGURE LEGENDS 
Figure 1. Selection criteria and resulting cohorts used in each analysis. 
 
Figure 2. Graphical representation of the results of the analyses of the long-term AIS 
outcomes. 
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TABLES 
Table 1. Patient characteristics in hospital, stratified by group membership. 
 
 Total Neither HF nor AF AF only HF only Both AF and HF P value* 
N 10,816 6668 2605 611 932  
Age, mean (SD) 77.9(12.1) 75.3(12.8) 82.2(8.8) 80.1 (10.7) 83.5(8.8) <0.001 
Sex, N(%) 
M 
F 
 
5192(48.0) 
5624(52.0) 
 
3371(50.6) 
3297(49.5) 
 
1128(43.3) 
1477(56.7) 
 
307(50.3) 
304(49.8) 
 
386(41.4) 
546(58.6) 
 
<0.001 
Outcomes 
In-hospital 
mortality, 
N (%) 
2035(18.8) 951(14.3) 586(22.5) 158(25.9) 340(36.5) <0.001 
Length of stay 
median (IQR) 
8.0(3.0-17.0) 7.0(3.0-15.0) 10.0(4.0-20.0) 11.0(4.0-21.2) 10.3(5.0-22.0) <0.001 
mRS admission 
median (IQR) 
0.0(0.0-2.0) 0.0(0.0-1.0) 0.0(0.0-2.0) 1.0(0.0-2.0) 1.0(0.0-3.0) <0.001 
mRS discharge 
median (IQR) 
3.0(1.0-6.0) 2.0(1.0-4.0) 4.0(2.0-6.0) 4.0(2.0-6.0) 5.0(3.0-6.0) <0.001 
ΔmRS 
median (IQR) 
2.0(0.0-3.0) 1.0(0.0-3.0) 2.0(1.0-4.0) 2.0(1.0-4.0) 3.0(1.0-4.0) <0.001 
OCSP classification 
LACS 
PACS 
POCS 
TACS 
Unknown, 
N (%) 
2484(24.4) 
3681(36.2) 
1611(15.8) 
1954(19.2) 
442(4.4) 
1733(27.6) 
2204(35.1) 
1112(17.7) 
949(15.1) 
278(4.4) 
458(18.8) 
934(38.4) 
320(13.2) 
625(25.7) 
97(4.0) 
 
136(23.2) 
215(36.7) 
85(14.5) 
122(20.8) 
28(4.8) 
157(17.9) 
328(37.4) 
94(10.7) 
258(29.5) 
39(4.5) 
<0.001 
Admission anti-thromobotic medication 
Antiplatelets 
admission 
3135(29.0) 1709(25.6) 854(32.8) 240(39.3) 332(25.6) <0.001 
Anticoagulants 
admission 
740(6.8) 93(1.4) 424(16.3) 11(1.8) 212(22.8) <0.001 
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Discharge anti-thrombotic medication 
Antiplatelets 
discharge 
7203(66.6) 4691(70.4) 903(34.7) 346(56.6) 262(28.1) <0.001 
Anticoagulants 
discharge 
1030(9.5) 153(2.3) 662(25.4) 30(4.9) 185(19.9) <0.001 
Pre-existing co-morbidities 
Coronary Heart 
Disease, N(%) 
2933(27.1%) 1282(19.2%) 756(29.0%) 373(61.0%) 522(56.0%) <0.001 
Peripheral 
Vascular Disease, 
N(%) 
430(4.0%) 196(2.9%) 107(4.1%) 51(8.3%) 76(8.2%) <0.001 
Transient 
Ischaemic attack, 
N(%) 
530(4.9%) 278(4.2%) 138(5.3%) 40(6.5%) 74(7.9%) <0.001 
Hypertension, 
N(%) 
6405(59.2%) 3580(53.7%) 1725(66.2%) 417(68.2%) 683(73.3%) <0.001 
Diabetes, N(%) 1901(17.6%) 1094(16.4%) 434(16.7%) 164(26.8%) 209(22.4%) <0.001 
Chronic Kidney 
Disease, N(%) 
 
693(6.4%) 274(4.1%) 152(5.8%) 102(16.7%) 165(17.7%) <0.001 
Asthma, N(%) 987(9.1%) 557(8.4%) 214(8.2%) 87(14.2%) 129(13.8%) <0.001 
Chronic 
Obstructive 
Pulmonary 
Disease, N(%) 
868(8.0%) 435(6.5%) 173(6.6%) 109(17.8%) 151(16.2%) <0.001 
Cancers, N(%) 1683(15.6%) 968(14.5%) 429(16.5%) 111(18.2%) 175(18.8%) <0.001 
Liver disease, 
N(%) 
167(1.5%) 107(1.6%) 27(1.0%) 10(1.6%) 23(2.5%) 0.02 
Dementia, N(%) 314(2.9%) 147(2.2%) 106(4.7%) 22(3.6%) 39(4.2%) <0.001 
Charlson co-
morbidity index, 
median (IQR) 
3(1-4) 2(1-4) 2(1-4) 5(3-6) 4(3-6) <0.001 
 
 Continous normally distributed variables displayed as mean (standard deviation). Non-normally variables displayed as mean (inter-quartile 
range). Categorical variables displayed as frequency (percentage). 
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* One-way ANOVA, the Kruskal-Wallis test and the Chi-squared test were used to test differences across groups for normally distributed, non-
normally distributed and categorical variables respectively. 
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Table 2. Results of the in-hospital anlayses. 
 No NIHSS adjustment NIHSS adjustment 
In-hospital death 
 OR[95%CI] P value OR[95%CI] P value 
No AF; No HF 1 (reference)  1 (reference)  
AF only 1.24[1.07-1.43] 0.004 1.23[1.06-1.42] 0.005 
HF only 1.40[1.10-1.79] 0.007 1.40[1.10-1.79] 0.007 
AF + HF 2.23[1.83-2.72] <0.001 2.22[1.82-2.70] < 0.001 
LoS* greater than median 
 OR[95%CI] P value OR [95%CI] P value 
No AF; No HF 1 (reference)  1 (reference)  
AF only 1.29[1.16-1.44] <0.001 1.29[1.16-1.44] <0.001 
HF only 1.85[1.50-2.28] <0.001 1.85[1.50-2.27] <0.001 
AF + HF 1.66[1.38-2.00] <0.001 1.66[1.38-2.00] <0.001 
Excess disability 
2nd ∆mRS† tertile vs 1st ∆mRS tertile 
 OR[95%CI] P value OR[95%CI] P value 
No AF; No HF 1 (reference)  1 (reference)  
AF only 1.06[0.91-1.25] 0.451 1.07[0.91-1.24] 0.414 
HF only 1.03[0.78-1.36] 0.841 1.07[0.80-1.41] 0.658 
AF + HF 0.86[0.67-1.09] 0.202 0.88[0.65-1.19] 0.408 
3rd ∆mRS tertile vs 1st ∆mRS tertile 
 OR[95%CI] P value OR[95%CI] P value 
No AF; No HF 1 (reference)  1 (reference)  
AF only 1.36[1.12-1.64] 0.002 1.38[1.15-1.65] <0.001 
HF only 1.27[0.85-1.89] 0.238 1.25[0.88-1.78] 0.205 
AF + HF 1.11[0.83-1.49] 0.470 1.14[0.82-1.58] 0.443 
 
All models were adjusted for age, sex, OCSP classification, pre-existing co-morbidities (ischaemic heart disease, peripheral vascular disease, 
transient ischaemic attack, previous stroke, hypertension, diabetes mellitus, chronic kidney disease, asthma, chronic obstructive pulmonary 
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disease, cancers, liver disease), admission plasma biochemical parameters (random plasma glucose, creatinine, sodium, albumin, cholesterol, 
INR, CRP, haemoglobin, white cell count, platelet count) and admission anti-thrombotic medication.  
 
Statistically significant results displayed in bold. 
 
*LoS: in-hospital length of stay 
†∆mRS: the difference in the modified Rankin Scale after and before the index stroke.  
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Table 3. Results of the long-term outcome analysis. 
Mortality 
 Post-discharge 
deaths(%) 
N* HR[95%CI] † P value 
No AF; No HF 1649(29.1) 5659 1 (reference)  
AF only 860(42.9) 2007 1.45[1.33-1.59] <0.001 
HF only 229(50.7) 452 2.07[1.83-2.36] <0.001 
AF + HF 330(56.2) 589 2.20[1.96-2.46] <0.001 
Recurrence 
 Recurrent 
stroke (%) 
N‡ HR [95%CI] † P value 
No AF; No HF 550(10.5) 5247 1 (reference)  
AF only 233(12.7) 1834 1.50[1.26-1.78] <0.001 
HF only 52(13.0) 400 1.33[1.01-1.75] 0.042 
AF + HF 59(11.5) 512 1.62[1.28-2.07] <0.001 
* Patients in each disease category at risk of death.  The median follow-up was  5.5 years. 
† Results of the Cox regression for long-term mortality and ischaemic stroke recurrence,adjusted for age, sex, pre-existing co-morbidities 
(ischaemic heart disease, peripheral vascular disease, transient ischaemic attack, previous stroke, hypertension, (diabetes mellitus, chronic 
kidney disease, asthma, chronic obstructive pulmonary disease, cancers, liver disease), discharge antithrombotic agents, the OCSP 
classificationand incident co-morbidities after hospital discharge (including incident haemorrhagic stroke) as time-updated binary variables in 
the regression model. The mortality analysis was adjusted for incident recurrent ischaemic strokes. 
‡ Patients in each disease category at risk of recurrent stroke The median follow-up was 3.7 years. 
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FIGURES 
Figure 1. Selection criteria and resulting cohorts used in each analysis. 
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Figure 2. Graphical representation of the results of the analyses of long-term AIS outcomes. 
 
 
 
